Affymetrix Announces Preliminary Revenue for Second Quarter 2011
July 06 2011 - 4:00PM
Business Wire
Affymetrix, Inc. (Nasdaq: AFFX) today reported that based on
preliminary financial data, the Company expects total revenue for
the second quarter of 2011 to be in the range of $64-65 million.
The Company expects product revenue for the second quarter of 2011
to be approximately $58-59 million, including consumable sales of
approximately $55 million and instrument sales of approximately
$3.5 million. Service revenue is expected to be about $5 million
and license and royalty revenue are expected to be about $1
million.
“During the second quarter we experienced decreased sales to
academic customers across all regions, particularly in North
America,” stated Andrew Last, executive vice president and chief
commercial officer. “Our consumable revenue was down by about 10%
from last year.”
“We are clearly disappointed with our revenue this quarter,”
stated Tim Barabe, executive vice president and CFO. “However, we
still expect to generate approximately $10 million in positive
cash-flow for the second quarter and to have a net cash position of
more than $155 million.”
The Company will provide further information when it reports
second quarter 2011 results after the close of the market on
Wednesday, July 27, 2011. Affymetrix’s management team will host a
conference call on July 27, 2010 at 2:00 p.m. PT. A live webcast
can be accessed by visiting the Investor Relations section of the
Company's website at http://www.affymetrix.com. In addition,
investors and other interested parties can listen by dialing
domestic: (877) 407-8291, international: (201) 689-8345. The
passcode for both replays is 375254.
About Affymetrix
Affymetrix technology is used by the world's top pharmaceutical,
diagnostic, and biotechnology companies, as well as leading
academic, government and nonprofit research institutes. More than
2,100 systems have been shipped around the world and more than
23,500 peer-reviewed papers have been published using the
technology. Affymetrix is headquartered in Santa Clara, Calif., and
has manufacturing facilities in Santa Clara, Cleveland, Ohio, and
Singapore. The company has about 900 employees worldwide and
maintains sales and distribution operations across Europe, Asia,
and Latin America. For more information about Affymetrix, please
visit http://www.affymetrix.com.
Affymetrix has not filed the Form 10-Q for the second quarter of
fiscal 2011. As a result, all financial results described in this
press release should be considered preliminary, and are subject to
change to reflect any necessary corrections or adjustments, or
changes in accounting estimates, that are identified prior to the
time the company is in a position to complete these filings.
All statements in this press release that are not historical are
"forward-looking statements" within the meaning of Section 21E of
the Securities Exchange Act as amended, including statements
regarding Affymetrix' "expectations," "beliefs," "hopes,"
"intentions," "strategies" or the like. Such statements are subject
to risks and uncertainties that could cause actual results to
differ materially for Affymetrix from those projected, including,
but not limited to: risks that the actual results for the second
quarter of 2011 will vary from the preliminary estimates reflected
in this release; risks related to the adoption of our new products,
risks related to past and future acquisitions; risks of the
company's ability to achieve and sustain higher levels of revenue,
higher gross margins and reduced operating expenses; uncertainties
relating to technological approaches, manufacturing and product
development; risks of personnel retention; uncertainties related to
cost and pricing of Affymetrix products; dependence on
collaborative partners; uncertainties relating to sole-source
suppliers; uncertainties relating to FDA and other regulatory
approvals; competition; risks relating to intellectual property of
others and the uncertainties of patent protection and litigation.
These and other risk factors are discussed in Affymetrix' Form 10-K
for the year ended December 31, 2010, and other SEC reports,
including its Quarterly Reports on Form 10-Q for subsequent
quarterly periods. Affymetrix expressly disclaims any obligation or
undertaking to release publicly any updates or revisions to any
forward-looking statements contained herein to reflect any change
in Affymetrix' expectations with regard thereto or any change in
events, conditions or circumstances on which any such statements
are based.
Affymetrix (NASDAQ:AFFX)
Historical Stock Chart
From Sep 2024 to Oct 2024
Affymetrix (NASDAQ:AFFX)
Historical Stock Chart
From Oct 2023 to Oct 2024